Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA

What Was Tested

This randomized controlled trial paper looks at Retatrutide and Glucagon.

According to current consensus guidelines for type 2 diabetes management, bodyweight management is as important as attaining glycaemic targets.

Who Took Part

By PubMed's age tags, the people studied were teenagers, young adults, adults, middle-aged adults and older adults, both men and women.

In this randomised, double-blind, double-dummy, placebo-controlled and active comparator-controlled, parallel-group, phase 2 trial, participants were recruited from 42 research and health-care centres in the USA.

Participants, study site personnel, and investigators were masked to treatment allocation until after study end.

How the Study Was Run

The design is described as randomized, double-blind, placebo-controlled and parallel-group.

The participants were allocated by chance, so the Retatrutide group and the comparison group should start out alike.

Blinding on both sides kept the participants and researchers unaware of who received Retatrutide.

A placebo (an inactive look-alike) gave the Retatrutide group a baseline to be compared against.

Groups ran in parallel: each of the participants stayed in one arm throughout.

The primary endpoint was change in HbA1c from baseline to 24 weeks, and secondary endpoints included change in HbA1c and bodyweight at 36 weeks.

The study is registered at ClinicalTrials.gov, NCT04867785.

What Was Measured

The subject headings attached to it are Blood Glucose, Diabetes Mellitus, Type 2, Glucagon, Glucagon-Like Peptide 1, Glucagon-Like Peptide-1 Receptor, Glucagon-Like Peptides and Glucose.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Retatrutide and Glucagon.

Its findings take up roughly 10 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2023 (Lancet (London, England)), a journal based in England.

More context: the Retatrutide compound page and the Glucagon compound page, all human trials.